Latest Daily News

Latest News

June 7, 2016

The Clinical Science Symposium, “Precision Medicine: Making Progress for Patient Benefit,” detailed 3 large-scale efforts leveraging innovative trial designs and cutting-edge technology to break critical ground in the ability to pinpoint and use viable targeted therapies for individual patients.

Read more

June 7, 2016

Because immune responses are evolving and dynamic over time, expression of a single biomarker to select patients for treatment will really not be feasible and we should not continue on the single biomarker path.

Read more
June 6, 2016

The session “The Immune System and Cancer,” discussed the nuts and bolts of and current thinking about immunology and cancer and the implications for future research and therapy. 

Read more

May 26, 2016

Several Education Sessions focus on the increasing importance of immunotherapies in oncology practice and on future research directions in the field. From currently approved checkpoint inhibitors to on-the-horizon ideas, these sessions offer glimpses into a promising area of cancer therapy.

Read more

May 26, 2016

The field of immuno-oncology has revolutionized cancer care over the past decade and continues to yield new, exciting results. ASCO, in collaboration with the Society for Immunotherapy of Cancer (SITC), will be holding its first symposium on immuno-oncology next year in Orlando, Florida.

Read more
May 21, 2015

In this article from 2013, Drs. Yujie Zhao and Alex A. Adjei discuss inhibiting MEK for cancer therapy.

Read more

May 21, 2015

In this article from 2012, Dr. Grant McArthur discusses how the RAS/RAF/MEK/ERK pathway functions in cancer.

Read more
May 29, 2015

Multiple studies indicate that mutant IDH is a valid target for cancer drug development in possibly addressing a broad range of solid and hematologic tumors.

Read more
May 30, 2015

Comparative effectiveness research is a new priority in cancer research and is increasing efficiency in research and changing everyday practice and policy.

Read more
May 30, 2015

Wendy Kohlmann, Marjan Champine, and Dr. Sarah Colonna present their thoughts on discussing genetic testing with patients and their families, including obtaining informed consent, explanation of mutations, and recommendations for genetic counseling.

Read more
May 31, 2015

Reasons for disappointing clinical activity initially seen in the biology and the significant of inhibiting PI3 kinase in HNSCC were discussed at this Annual Meeting Education Session. 

Read more
May 31, 2015

Results from the phase III IFCT-GFPC-0701 MAPS trial found that the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma prolonged overall survival by 2.75 months.

Read more
May 31, 2015

Advances made in next generation sequencing have allowed germline mutations to be increasingly identified in tumors and normal DNA. The significance of these findings, including whether results arising from germline testing should be returned to patients, was discussed during this session.

Read more
June 7, 2015

An Education Session at the ASCO Annual Meeting reviewed data on neoadjuvant and adjuvant therapy, targeted therapies for metastatic disease, and management of brain metastases.

Read more
June 7, 2015

Two randomized phase III trials, PANORAMA-1 and ASPIRE have recently demonstrated improved response rates in patients with relapsed and refractory myeloma. The regimen of carfilzomib plus lenalidomide and dexamethasone used in ASPIRE achieved progression-free survival of 26 months. 

Read more
June 10, 2015

The addition of the tumor treating fields device to adjuvant temozolomide for patients with glioblastoma demonstrated an improvement in progression-free survival and overall survival.

Read more
June 7, 2015

The CD38-targeted monoclonal antibody daratumumab shows promising single-agent activity in patients with heavily pretreated relapsed and refractory multiple myeloma. 

Read more
May 31, 2015

Advances in cancer medicine and technology was the topic of discussion at this Annual Meeting Education Session regarding information retrieval, social media, and the application of technology to patient-reported outcomes.

Read more